UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis

Veterinary dermatology, 2013-02, Vol.24 (1), p.48-e12

2013

Volltextzugriff (PDF)

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

Molecular cancer therapeutics, 2008-07, Vol.7 (7), p.1880-1889

2008

Volltextzugriff (PDF)

Current understanding of the pathophysiologic mechanisms of canine atopic dermatitis

Journal of the American Veterinary Medical Association, 2012-07, Vol.241 (2), p.194-207

2012

Volltextzugriff (PDF)

Allergen-induced production of IL-31 by canine Th2 cells and identification of immune, skin, and neuronal target cells

Veterinary immunology and immunopathology, 2014-01, Vol.157 (1-2), p.42-48

2014

Volltextzugriff (PDF)

Oclacitinib (APOQUEL®) is a selective Janus kinase 1 inhibitor with efficacy in a canine model of flea allergic dermatitis

Journal of veterinary pharmacology and therapeutics, 2024-11, Vol.47 (6), p.447-453

2024

Volltextzugriff (PDF)

Update on pathogenesis, diagnosis, and treatment of atopic dermatitis in dogs

Journal of the American Veterinary Medical Association, 2019-06, Vol.254 (11), p.1291-1300

2019

Volltextzugriff (PDF)

Speed of onset of a new chewable formulation of oclacitinib maleate (Apoquel®) in a canine model of IL‐31‐induced pruritus

Journal of veterinary pharmacology and therapeutics, 2022-07, Vol.45 (4), p.380-384

2022

Volltextzugriff (PDF)

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

Cancer research (Chicago, Ill.), 2007-12, Vol.67 (24), p.11924-11932

2007

Volltextzugriff (PDF)

Cytokine transcriptome profiling in acute experimental canine atopic dermatitis skin lesions after IL‐31 inhibition with lokivetmab

Veterinary dermatology, 2023-08, Vol.34 (4), p.327-338

2023

Volltextzugriff (PDF)

Onset and duration of action of lokivetmab in a canine model of IL‐31 induced pruritus

Veterinary dermatology, 2021-12, Vol.32 (6), p.681-e182

2021

Volltextzugriff (PDF)

Lack of Interference of Oclacitinib with the results of intradermal testing or allergen-specific IgE serology in Dermatophagoides farinae-sensitized beagle dogs

Veterinary immunology and immunopathology, 2023-02, Vol.256, p.110537-110537, Article 110537

2023

Volltextzugriff (PDF)

Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4‑d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family

Journal of medicinal chemistry, 2016-09, Vol.59 (17), p.8103-8124

2016

Volltextzugriff (PDF)

Cytokine expression in feline allergic dermatitis and feline asthma

Veterinary dermatology, 2021-12, Vol.32 (6), p.613-e163

2021

Volltextzugriff (PDF)

In Pursuit of an Allosteric Human Tropomyosin Kinase A (hTrkA) Inhibitor for Chronic Pain

ACS medicinal chemistry letters, 2021-11, Vol.12 (11), p.1847-1852

2021

Volltextzugriff (PDF)

IL-31-induced pruritus in dogs: a novel experimental model to evaluate anti-pruritic effects of canine therapeutics

Veterinary dermatology, 2016-02, Vol.27 (1), p.34-e10

2016

Volltextzugriff (PDF)

Serum concentrations of IL‐31 in dogs with nonpruritic mast cell tumours or lymphoma

Veterinary dermatology, 2020-12, Vol.31 (6), p.466-e124

2020

Volltextzugriff (PDF)

Tyrosine Kinase Inhibitors. 19. 6-Alkynamides of 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-d]pyrimidines as Irreversible Inhibitors of the erbB Family of Tyrosine Kinase Receptors

Journal of medicinal chemistry, 2006-02, Vol.49 (4), p.1475-1485

2006

Volltextzugriff (PDF)

Induction of Apoptosis by Cationic Amphiphilic Drugs Amiodarone and Imipramine

Drug and chemical toxicology (New York, N.Y. 1978), 2005, Vol.28 (1), p.117-133

2005

Volltextzugriff (PDF)

Interleukin‐31: its role in canine pruritus and naturally occurring canine atopic dermatitis

Veterinary dermatology, 2013-02, Vol.24 (1), p.48

2013

Volltextzugriff (PDF)

G1 cell cycle arrest due to the inhibition of erbB family receptor tyrosine kinases does not require the retinoblastoma protein

Experimental cell research, 2005-02, Vol.303 (1), p.56-67

2005

Volltextzugriff (PDF)

Induction of Apoptosis in Rat Peripheral Blood Lymphocytes by the Anticancer Drug CI‐994 (Acetyldinaline)

BioMed research international, 2001-01, Vol.1 (2), p.52-61

2001

Volltextzugriff (PDF)

Kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-88204E

Biochemistry (Easton), 1993-07, Vol.32 (26), p.6548-6554

1993

Volltextzugriff (PDF)

Altered bcl-2 family expression during non-genotoxic hepatocarcinogenesis in mice

Carcinogenesis (New York), 1999-08, Vol.20 (8), p.1583-1590

1999

Volltextzugriff (PDF)

Attenuation of G1 checkpoint function by the non-genotoxic carcinogen phenobarbital

Carcinogenesis (New York), 1998-07, Vol.19 (7), p.1173-1183

1998

Volltextzugriff (PDF)

Chemical transformation of mouse liver cells results in altered cyclin D-CDK protein complexes

Carcinogenesis (New York), 1998-06, Vol.19 (6), p.1093-1102

1998

Volltextzugriff (PDF)

1 – 25 von 144

Suche als RSS-Feed

Aktive Filter

PublikationsformTagungsberichte

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(129)
Mit Volltextzugriff
(128)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Interleukin-31: its role in canine pruritus and naturally occurring canine atopic dermatitis

Antitumor activity and pharmacokinetic properties of PF-00299804, a second-generation irreversible pan-erbB receptor tyrosine kinase inhibitor

Current understanding of the pathophysiologic mechanisms of canine atopic dermatitis

Allergen-induced production of IL-31 by canine Th2 cells and identification of immune, skin, and neuronal target cells

Oclacitinib (APOQUEL®) is a selective Janus kinase 1 inhibitor with efficacy in a canine model of flea allergic dermatitis

Update on pathogenesis, diagnosis, and treatment of atopic dermatitis in dogs

Speed of onset of a new chewable formulation of oclacitinib maleate (Apoquel®) in a canine model of IL‐31‐induced pruritus

PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib

Cytokine transcriptome profiling in acute experimental canine atopic dermatitis skin lesions after IL‐31 inhibition with lokivetmab

Onset and duration of action of lokivetmab in a canine model of IL‐31 induced pruritus

Lack of Interference of Oclacitinib with the results of intradermal testing or allergen-specific IgE serology in Dermatophagoides farinae-sensitized beagle dogs

Tyrosine Kinase Inhibitors. 20. Optimization of Substituted Quinazoline and Pyrido[3,4‑d]pyrimidine Derivatives as Orally Active, Irreversible Inhibitors of the Epidermal Growth Factor Receptor Family

Cytokine expression in feline allergic dermatitis and feline asthma

In Pursuit of an Allosteric Human Tropomyosin Kinase A (hTrkA) Inhibitor for Chronic Pain

IL-31-induced pruritus in dogs: a novel experimental model to evaluate anti-pruritic effects of canine therapeutics

Serum concentrations of IL‐31 in dogs with nonpruritic mast cell tumours or lymphoma

Tyrosine Kinase Inhibitors. 19. 6-Alkynamides of 4-Anilinoquinazolines and 4-Anilinopyrido[3,4-d]pyrimidines as Irreversible Inhibitors of the erbB Family of Tyrosine Kinase Receptors

Induction of Apoptosis by Cationic Amphiphilic Drugs Amiodarone and Imipramine

Interleukin‐31: its role in canine pruritus and naturally occurring canine atopic dermatitis

G1 cell cycle arrest due to the inhibition of erbB family receptor tyrosine kinases does not require the retinoblastoma protein

Induction of Apoptosis in Rat Peripheral Blood Lymphocytes by the Anticancer Drug CI‐994 (Acetyldinaline)

Kinetic studies with the non-nucleoside HIV-1 reverse transcriptase inhibitor U-88204E

Altered bcl-2 family expression during non-genotoxic hepatocarcinogenesis in mice

Attenuation of G1 checkpoint function by the non-genotoxic carcinogen phenobarbital

Chemical transformation of mouse liver cells results in altered cyclin D-CDK protein complexes

Aktive Filter

Suchergebnisse filtern